We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

69 hedge funds and large institutions have $93.6M invested in Protagonist Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

9.14% more ownership

Funds ownership: 56.56% → 65.7% (+9.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

1% less funds holding

Funds holding: 70 → 69 (-1)

9% less capital invested

Capital invested by funds: $103M → $93.6M (-$8.9M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
27
Reduced
22
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
GPP
Great Point Partners
Connecticut
+$11.3M
2
BI
BVF Inc
California
+$7.77M
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.27M
4
Deutsche Bank
Deutsche Bank
Germany
+$2.14M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.75M

Top Sellers

1
EC
EcoR1 Capital
California
-$9.31M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.84M
3
BlackRock
BlackRock
New York
-$3.33M
4
PI
Pharmstandard International
Luxembourg
-$1.78M
5
State Street
State Street
Massachusetts
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$21.4M +$115K +15,017 +0.5%
GPP
2
Great Point Partners
Connecticut
$9.9M +$11.3M +1,473,609 New
BI
3
BVF Inc
California
$9.53M +$7.77M +1,012,367 +250%
FCM
4
Farallon Capital Management
California
$6.12M -$793K -103,271 -10%
PI
5
Pharmstandard International
Luxembourg
$5.04M -$1.78M -231,638 -24%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.48M -$56.1K -7,304 -1%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$3.36M -$3.84M -500,000 -50%
Renaissance Technologies
8
Renaissance Technologies
New York
$3.21M +$3.27M +426,100 +816%
CAM
9
Cormorant Asset Management
Massachusetts
$2.57M – – –
Deutsche Bank
10
Deutsche Bank
Germany
$1.98M +$2.14M +279,174 +1,859%
BlackRock
11
BlackRock
New York
$1.71M -$3.33M -433,125 -63%
AIM
12
Alambic Investment Management
California
$1.57M +$1.51M +196,353 +521%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$1.57M +$1.35M +175,849 +303%
Millennium Management
14
Millennium Management
New York
$1.53M -$710K -92,458 -29%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$1.53M +$1.75M +227,817 New
TCM
16
Tekla Capital Management
Massachusetts
$1.47M – – –
Two Sigma Investments
17
Two Sigma Investments
New York
$1.19M +$1.11M +144,679 +441%
OAM
18
Oxford Asset Management
United Kingdom
$1.12M -$14.9K -1,939 -1%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$1.06M +$851K +110,800 +235%
American Century Companies
20
American Century Companies
Missouri
$995K +$40.2K +5,242 +4%
SIM
21
Spark Investment Management
New York
$929K +$435K +56,600 +69%
Citadel Advisors
22
Citadel Advisors
Florida
$883K +$631K +82,204 +167%
First Manhattan
23
First Manhattan
New York
$861K -$124K -16,200 -11%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$846K -$120K -15,657 -11%
Man Group
25
Man Group
United Kingdom
$579K +$661K +86,126 New
1
2 3 4

PTGX Hedge Fund Activity: Q2 2018 in Review

69 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2018, worth a combined $93.6M — down 8.7% from $103M a quarter earlier.

Fund positioning in PTGX was balanced in Q2 2018: 17 funds opened new positions, 17 closed out, 27 added to existing stakes and 22 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $11.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $9.31M sold.

  • 69 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2018, down from 70 in Q1 2018.
  • Funds reported $93.6M of Protagonist Therapeutics stock for Q2 2018, down 8.7% quarter-over-quarter.
  • 17 funds opened new Protagonist Therapeutics positions in Q2 2018 and 17 closed out, a net change of 0 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2018 was Great Point Partners, an estimated $11.3M added.
  • The largest Protagonist Therapeutics seller in Q2 2018 was EcoR1 Capital, an estimated $9.31M sold.

Based on aggregated 13F filings for Q2 2018.